Pharming Group NV (PHAR)

Amsterdam
Currency in EUR
0.748
+0.043(+6.10%)
Closed·
PHAR Scorecard
Full Analysis
High shareholder yield
Unusual trading volume
Fair Value
Day's Range
0.7120.755
52 wk Range
0.6480.969
Key Statistics
Edit
Prev. Close
0.705
Open
0.712
Day's Range
0.712-0.755
52 wk Range
0.648-0.969
Volume
12.76M
Average Vol. (3m)
6.16M
1-Year Change
-21.67%
Book Value / Share
0.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHAR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.900
Upside
+154.01%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Pharming Group NV Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Employees
404

Compare PHAR to Peers and Sector

Metrics to compare
PHAR
Peers
Sector
Relationship
P/E Ratio
−48.9x−3.5x−0.5x
PEG Ratio
4.300.000.00
Price / Book
2.6x2.7x2.6x
Price / LTM Sales
2.0x10.3x2.9x
Upside (Analyst Target)
160.7%276.3%64.0%
Fair Value Upside
Unlock7.6%9.4%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1.900
(+154.01% Upside)

Earnings

Latest Release
Apr 03, 2025
EPS / Forecast
-- / -0.01
Revenue / Forecast
92.67M / --
EPS Revisions
Last 90 days

People Also Watch

18.22
CORB
+4.00%
19.24
FASTN
+2.01%
5.95
BSGR
0.00%
2.381
ALRIB
+0.89%
6.44
CMCOM
+4.55%

FAQ

What Is the Pharming Group (PHAR) Stock Price Today?

The Pharming Group stock price today is 0.748

What Stock Exchange Does Pharming Group Trade On?

Pharming Group is listed and trades on the Amsterdam stock exchange.

What Is the Stock Symbol for Pharming Group?

The stock symbol for Pharming Group is "PHAR."

What Is the Pharming Group Market Cap?

As of today, Pharming Group market cap is 511.58M.

What is Pharming Group Earnings Per Share?

The Pharming Group EPS is -0.02.

From a Technical Analysis Perspective, Is PHAR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.